Medifast Inc key statistics and ratios

In fiscal 2025, Medifast Inc had return on equity of -9.1%, an operating margin of -3.7%, debt equal to 0.0% of equity and a current ratio of 4.69. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Medifast Inc: financial ratios, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Gross margin	73.3%	74.7%	75.3%	74.1%	74.2%	73.3%	73.8%	74.9%	75.5%	75.8%	75.2%	74.6%	73.9%	71.3%	72.4%	73.8%	71.3%	69.2%
Operating margin	10.9%	12.3%	9.2%	8.5%	11.9%	10.6%	10.5%	9.8%	13.1%	13.8%	12.8%	14.4%	14.2%	11.6%	11.8%	0.5%	−3.7%	−11.6%
Net margin	6.7%	7.6%	6.2%	5.0%	7.4%	4.6%	7.4%	6.5%	9.2%	11.1%	10.9%	11.0%	10.7%	9.0%	9.3%	0.3%	−4.8%	−13.6%
Free-cash-flow margin	8.3%	6.5%	6.9%	10.1%	9.6%	6.5%	9.7%	8.2%	13.3%	11.2%	10.4%	14.9%	4.0%	11.1%	13.2%	2.8%	0.3%	−1.3%
Return on equity	23.8%	32.7%	25.5%	19.3%	25.3%	14.7%	23.7%	19.3%	27.4%	51.7%	72.8%	78.5%	91.2%	80.3%	55.8%	1.0%	−9.1%	−21.5%
Return on assets	—	20.8%	18.6%	13.5%	18.2%	10.6%	17.3%	15.0%	20.8%	35.4%	42.8%	43.7%	48.6%	40.2%	31.8%	0.7%	−7.0%	−16.8%
Asset turnover	—	2.74	2.99	2.70	2.47	2.30	2.35	2.31	2.26	3.18	3.92	3.97	4.53	4.47	3.42	2.03	1.45	1.23
Current ratio	—	3.80	3.16	3.08	3.39	3.04	3.69	4.15	3.37	2.41	1.94	2.10	1.81	1.58	2.43	3.34	4.69	4.82
Debt to equity	0.0%	7.8%	6.5%	4.0%	0.2%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	127.6x	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Effective tax rate	38.4%	38.1%	33.0%	35.0%	30.5%	33.6%	34.1%	34.2%	31.3%	20.9%	15.6%	23.4%	24.1%	22.0%	22.8%	44.8%	—	—
R&D as % of revenue	—	—	—	—	—	0.5%	0.7%	0.7%	0.5%	0.4%	0.4%	0.3%	0.3%	0.3%	0.4%	0.8%	1.1%	—
SG&A as % of revenue	62.4%	62.4%	66.1%	65.5%	62.4%	62.7%	63.3%	65.1%	62.4%	62.0%	62.5%	60.3%	59.7%	59.8%	60.6%	73.3%	75.0%	80.8%
Capital spending as % of revenue	3.0%	4.7%	4.8%	2.6%	3.5%	2.5%	1.0%	1.0%	1.1%	1.0%	1.4%	0.6%	2.2%	1.0%	0.6%	1.2%	1.5%	1.3%
Free cash flow ÷ net income	123.6%	85.2%	111.1%	202.4%	129.2%	140.4%	132.6%	126.0%	144.3%	100.2%	95.2%	135.4%	36.8%	123.9%	142.0%	814.1%	—	—
Dividends ÷ net income	—	—	—	—	—	—	—	66.7%	55.5%	41.5%	45.4%	51.7%	38.9%	49.9%	73.4%	34.2%	—	—
Dividends and buybacks ÷ free cash flow	0.7%	0.2%	99.0%	8.6%	64.8%	183.1%	39.5%	52.9%	38.5%	95.1%	92.3%	41.8%	198.6%	111.3%	54.3%	4.2%	15.6%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Medifast Inc: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	74.1%	72.8%	72.6%	69.5%	69.4%	68.1%	69.9%	69.5%
Operating margin	0.6%	−1.1%	−1.0%	−4.6%	−10.4%	−4.3%	−5.7%	−26.9%
Net margin	0.7%	−0.7%	2.3%	−2.5%	−24.1%	−2.8%	−4.1%	−24.3%
Free-cash-flow margin	−6.1%	1.6%	−4.5%	12.0%	−8.8%	−1.1%	1.0%	4.0%
Current ratio	3.34	3.52	4.47	4.45	4.69	4.80	4.86	4.82
SG&A as % of revenue	73.5%	73.9%	73.6%	74.1%	79.8%	72.4%	75.6%	96.3%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · September 30, 2026

What it owns · $240m

Short-term assets $202mLonger-term assets $38m

What it owes, and who funded it · $240m

Short-term liabilities $42mLonger-term liabilities $18mShareholders' equity $180m

Short-term assets cover short-term liabilities $202m of assets due within a year against $42m of liabilities due within a year.
Short-term assets cover long-term liabilities $202m short-term assets against $18m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Medifast Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

75 /100

Strong moat

How hard Medifast's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Cash operating profit has been a median 28.0% of total assets over 10 years.
Pricing power 20 / 20

Gross margin has been a median 74.0%, moving by 2.0 percentage points (standard deviation) across 10 years.
Durability 3 / 20

Operating margin has been a median 12.6%; its worst year was -11.6%.
Cash conversion 13 / 20

Free cash flow was positive in 9 of 10 years, at a median 8.6% of revenue.
Discipline 19 / 20

The diluted share count fell 6.7% over five years; stock-based pay has been a median 0.7% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: LWAY vs MED BRID vs MED MAMA vs MED

More: Packaged Foods & Meats stocks compared, Consumer Staples sector, rankings of US companies

Figures from Medifast Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Medifast Inc.